Sherman Morris, Takayama Yuji
Department of Medicine, University of Toronto and Toronto General Hospital, EN9-223, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
Gastroenterol Clin North Am. 2004 Sep;33(3):671-91, xi. doi: 10.1016/j.gtc.2004.04.012.
Surveillance for hepatocellular carcinoma (HCC) has become routine despite a lack of evidence of efficacy. Suitable candidates for surveillance include patients with cirrhosis and some subsets of noncirrhotic chronic hepatitis B carriers. The best surveillance testis ultrasonography at 6- to 12-month intervals. Serological tests are less effective. Defining an abnormal result is difficult in the cirrhotic liver. Diagnosis requires radiological investigations and may require a biopsy if the lesion is between 1 and 2 cm in diameter. In the face of an abnormal surveillance test and failure to confirm the diagnosis initially, enhanced follow-up is required. HCC can be treated for cure by liver transplantation, resection, or local ablation. For patients with suitable lesions, liver transplantation offers the best form of therapy. Chemoembolization offers increased survival over no therapy. Several experimental therapies are being investigated.
尽管缺乏疗效证据,但肝细胞癌(HCC)监测已成为常规做法。适合进行监测的对象包括肝硬化患者和部分非肝硬化慢性乙型肝炎携带者。最佳的监测检查是每隔6至个月进行一次超声检查。血清学检查效果较差。在肝硬化肝脏中定义异常结果很困难。诊断需要进行放射学检查,如果病变直径在1至2厘米之间,可能需要进行活检。面对监测检查异常且最初未能确诊的情况,需要加强随访。HCC可以通过肝移植、切除或局部消融进行根治性治疗。对于有合适病变的患者,肝移植是最佳的治疗方式。化疗栓塞比不治疗能提高生存率。正在研究几种实验性疗法。